Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. METHODS: In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days (range, 30 to 42). The main secondary efficacy outcome was major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism). The primary safety outcome was major bleeding. RESULTS: A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 2.6%; 95% confidence interval [CI], 1.5 to 3.7; P<0.001). Major venous thromboembolism occurred in 4 of 1686 patients (0.2%) in the rivaroxaban group and in 33 of 1678 patients (2.0%) in the enoxaparin group (absolute risk reduction, 1.7%; 95% CI, 1.0 to 2.5; P<0.001). Major bleeding occurred in 6 of 2209 patients (0.3%) in the rivaroxaban group and in 2 of 2224 patients (0.1%) in the enoxaparin group (P=0.18). CONCLUSIONS: A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationThe Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Self-citationRoentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Self-citationRosencher, N., Kerkkamp, H. E. M., Macheras, G., Munuera, L. M., Menichella, G., Barton, D. M., Cremers, S., Abraham, I. L., & Investigation, F. T. O. (2003) · Transfusion · doi:10.1046/j.1537-2995.2003.00348.x · Cited by 603
Eikelboom, J. W., Quinlan, D. J., & Douketis, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05249-1 · Cited by 513
Research works printed but not linked: 1
- 10.1016/s0140-6736(07)61445-7 · DOI · Paper page
Cited by
Items 901–1,000 of 1,000
Novel antithrombotic agents for atrial fibrillation
Niespialowska-Steuden, M., Markides, V., & Gorog, D. A. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.02.006 · Cited by 6
“The RECORD (Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism) studies confirmed the superiority of rivaroxaban over standard anticoagulant therapy in VTE prevention following orthopedic surgery (Eriksson et al., 2008; Lassen et al., 2008).”
BackgroundBreen, K. A., & Hunt, B. J. (2011) · Clinical Medicine · doi:10.7861/clinmedicine.11-5-467 · Cited by 5
Tranexamic acid versus fibrin sealant in primary total hip replacement: a comparative study
Mahmood, A., Sawalha, S., Borbora, A., Kumar, G., & Peter, V. K. (2017) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-017-1910-3 · Cited by 5
Chyou, J. Y., Mega, J. L., & Sabatine, M. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00004-7 · Cited by 6
Chapter 9 Recent Advances in Coagulation Serine Protease Inhibitors
Smallheer, J. M., & Quan, M. L. C. (2009) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(09)04409-1 · Cited by 5
Schulman, S. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-10-0730 · Cited by 5
Jung, Y. J. (2025) · Journal of Metabolic and Bariatric Surgery · doi:10.17476/jmbs.2025.14.2.131 · Cited by 5
“Rivaroxaban, approved for thromboprophylaxis in orthopedic procedures, does not require dose adjustment in patients with extreme obesity [24,25].”
Prophylaxis of venous thromboembolism in trauma: What you need to know
Lippincott, M., & Berndtson, A. E. (2025) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000004871 · Cited by 4
Nuevas perspectivas clínicas en el uso de los anticoagulantes orales directos
Marco, P., Zamorano, J. L., Chana, F., & Llau, J. V. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.05.002 · Cited by 6
Herschman, M. A., Rigelsky, F. S., & Axtell, S. S. (2016) · PubMed Central · Cited by 5
Gao, X., Liu, Y., Zheng, D., Li, Y., Li, H., Xiong, X., Chen, H., Wang, H., Yu, X.-Y., Qu, K., et al. (2023) · Renal Failure · doi:10.1080/0886022x.2022.2163505 · Cited by 4
“However, these prophylactic anticoagulants have several limitations, including poor patient compliance with low-molecularweight heparin owing to cold storage and intravenous administration [16], the high cost of direct oral anticoagulants [17], various warfarin-related complications [18,19], and aspirin’s limited effi…”
BackgroundMeng, W., Wu, X., Wang, L., Gu, Z., Tu, Y., Zhang, L., Zhang, J., Xie, H., Zhou, Q., Chu, Y., et al. (2024) · Kidney Diseases · doi:10.1159/000540107 · Cited by 5
Pititto, G. N., Maraziti, G., Squizzato, A., & Becattini, C. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2628-3967 · Cited by 7
Venous Thromboembolism in Orthopaedic Surgery
Justin, R., & Michael, H. (2012) · InTech eBooks · doi:10.5772/31770 · Cited by 4
“There have been four phase III clinical trials comparing rivaroxaban to enoxaparin (Eriksson et al., 2008).”
BackgroundThromboseprophylaxe in der muskuloskelettalen Chirurgie
Pabinger-Fasching, I., Eichinger-Hasenauer, S., Grohs, J. G., Hochreiter, J., Kastner, N., Korninger, H. C., Kozek‐Langenecker, S. A., Marlovits, S., Niessner, H., Rachbauer, F., et al. (2014) · Wiener klinische Wochenschrift · doi:10.1007/s00508-014-0509-5 · Cited by 5
“541 HTEP-Patienten in einer Dosis von 10 mg täglich mit 40 mg Enoxaparin verglichen [31].”
Rivaroxaban in preventing venous thromboembolism after arthroplastic surgery in Taiwan
Mao, Y., Chen, S., Chen, C., Hsieh, K., & Gan, K. (2015) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2015.08.003 · Cited by 4
Liew, A., Eikelboom, J. W., & O'Donnell, M. J. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12440 · Cited by 4
Knepper, J., Ramacciotti, E., & Wakefield, T. W. (2011) · Phlebology The Journal of Venous Disease · doi:10.1258/phleb.2010.010023 · Cited by 4
Aizman, A., Abbott, E., & Rojas, L. E. (2011) · Revista médica de Chile · doi:10.4067/s0034-98872011000900016 · Cited by 10
Understanding the New Emerging Oral Anticoagulants for Venous Thromboembolism Prophylaxis
Welle, M. K. (2012) · Orthopaedic Nursing · doi:10.1097/nor.0b013e31826649a0 · Cited by 5
Anticoagulantes directos y Enfermería: un abordaje desde la seguridad clínica
Ruiz, A. R., Romero-Arana, A., & Gómez-Salgado, J. C. (2017) · Enfermería Clínica · doi:10.1016/j.enfcli.2017.02.003 · Cited by 4
Schrör, K., & Rauch, B. H. (2013) · HAL · Cited by 4
Tromboembolísmo venoso postoperatorio
Valencia, A. W., & Luque, J. S. H. (2010) · Colombian Journal of Anesthesiology · doi:10.1016/s0120-3347(10)84007-9 · Cited by 4
Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerations
Borris, L. C. (2010) · Journal of Blood Medicine · doi:10.2147/jbm.s6543 · Cited by 4
Self-citationMeddahi, S., & Samama, M. M. (2014) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2014.02.001 · Cited by 4
Implementing a venous thromboembolism (VTE) prevention strategy
Brockbank, K., Snoxall, S., Beaumont, A., Davies, P., Kershaw, M., Kirman, R., Murray, E., Pheby, A., Webb, I., Willman, E., et al. (2010) · Clinical Governance An International Journal · doi:10.1108/14777271011017347 · Cited by 4
“The new oral anticoagulant, Rivaroxaban, was later introduced as standard prophylaxis for patients undergoing total hip or knee replacements in light of Phase 3 trial evidence of its effectiveness in this situation ( Erikkson et al. , 2008”
BackgroundPharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes
Gopalakrishnan, L., Kumar, V. M., Kohli, P., Singh, P., Rastogi, U., & Gibson, C. M. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.688026 · Cited by 4
“If approved in the ACS indication by the FDA and EMA, rivaroxaban is a direct FXa inhibitor that is safe and effective across a variety of therapeutic indications including VTE, AF and ACS.”
BackgroundInfluentialSychev, D. A., Minnigulov, R., Ryzhikova, K., Yudina, I. Y., Lychagin, A. V., & Морозова, Т. Е. (2018) · Bulletin of Russian State Medical University · doi:10.24075/brsmu.2018.068 · Cited by 4
Montone, R. A., Niccoli, G., Tufaro, V., Minelli, S., Russo, M., Vergni, F., Sommariva, L., Pelliccia, F., Bedogni, F., & Crea, F. (2019) · Advances in Interventional Cardiology · doi:10.5114/aic.2019.83772 · Cited by 4
Ali, I., Elbana, H., Farhan, M. J., Qureshi, I. F., & Mubashir, A. (2020) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-020-02306-3 · Cited by 4
Thromboprophylaxis across orthopaedic surgery: Bibliometric analysis of the most cited articles
Sedani, A. B., Yakkanti, R. R., Allegra, P. R., Mattingly, L. G., & Aiyer, A. A. (2021) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2020.12.015 · Cited by 4
Trevisol, A. R., Coppi, E. F. M., Pancotte, J., Bortoluzzi, E. C., & Knop, G. P. (2017) · Revista Brasileira de Ortopedia · doi:10.1016/j.rbo.2017.05.018 · Cited by 4
Khatkar, H., Elahi, Z., See, A., McDonald, S., & Neal-Smith, G. (2022) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2022.101782 · Cited by 4
Gestion péri-opératoire des patients traités par antithrombotiques en chirurgie orale. Argumentaire
(2015) · Médecine Buccale Chirurgie Buccale · doi:10.1051/mbcb/2015037 · Cited by 10
Patient Blood Management in Vascular Surgery
Gyi, R., Cho, B. C., & Hensley, N. B. (2022) · Anesthesiology Clinics · doi:10.1016/j.anclin.2022.08.007 · Cited by 4
Thromboprophylaxis in gynaecology: a review of current evidence
Nambiar, D., Thachil, J. V., Yoong, W., & Nair, D. B. (2022) · The Obstetrician & Gynaecologist · doi:10.1111/tog.12849 · Cited by 4
Uthoff, H., Teruzzi, E., Boesch, P., Hofer, M., Spinedi, L., Bossart, S., Staub, D., & Keo, H. H. (2023) · VASA · doi:10.1024/0301-1526/a001080 · Cited by 4
Adam, S. S., McDuffie, J. R., Lachiewicz, P. F., Ortel, T. L., & Williams, J. W. (2012) · Europe PMC (PubMed Central) · Cited by 5
Nuevos anticoagulantes orales: una visión multidisciplinaria
Arcelus, J. I., Cairols, M. A., Xiberta, X. G., Jiménez, D., Llau, J. V., Monréal, M., & Vicente, V. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2009.03.027 · Cited by 5
Nuevos anticoagulantes orales en la prevención de la enfermedad tromboembólica venosa
Bosch, M., & Broto, P. L. (2010) · Medicina Clínica · doi:10.1016/j.medcli.2009.10.020 · Cited by 5
Novel Oral Anticoagulants for the Prevention and Treatment of Thromboembolism
Oliphant, C. S., Jacobs, A. R., Kabra, R., & Das, P. (2013) · Future Cardiology · doi:10.2217/fca.13.76 · Cited by 4
“3014) [34,35]”
BackgroundStacy, Z. A. (2013) · Europe PMC (PubMed Central) · Cited by 8
Intermittent pneumatic compression and pharmacologic thrombosis prophylaxis
Caprini, J. A. (2009) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32832d6c75 · Cited by 4
Prophylaxis for Deep Vein Thrombosis and Pulmonary Embolism in the Surgical Patient
Galanis, T., Kraft, W. K., & Merli, G. J. (2011) · Advances in Surgery · doi:10.1016/j.yasu.2011.05.001 · Cited by 5
“001) [66].”
New anticoagulants in the prevention and treatment of venous thromboembolism
Keltai, M., & Keltai, K. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29140 · Cited by 5
Complications Following Total Hip Arthroplasty
Rajpura, A., & Boar, T. (2013) · InTech eBooks · doi:10.5772/53030 · Cited by 4
Neue orale direkte Antikoagulanzien: Viele Vorteile, aber offene Fragen
Haas, S. K., & Schellong, S. (2014) · Der Internist · doi:10.1007/s00108-013-3424-3 · Cited by 5
Self-citationPreoperative and postoperative care in gynaecology
Croissant, K., & Shafi, M. I. (2009) · Obstetrics Gynaecology & Reproductive Medicine · doi:10.1016/j.ogrm.2008.11.007 · Cited by 4
Update in New Medications for Primary Care
Smetana, G. W., & Sillman, J. S. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0823-6 · Cited by 4
Will One Size of Anticoagulant Dosage Fit All?
Bloemen, S., de Laat, M., de Laat, B., Hemker, H. C., & Dieri, R. A. (2013) · Drug Development Research · doi:10.1002/ddr.21097 · Cited by 6
“Recent clinical evaluations of direct inhibitors of factor Xa [Eriksson et al., 2008; Lassen et al., 2008] or thrombin [Eriksson et al., 2007a, 2007b] indicate that these new drugs are noninferior and no less effective for thromboprophylaxis in AF and after major joint surgery compared with…”
BackgroundPerioperative Management of Oral Anticoagulants: A Focus on Target-Specific Oral Anticoagulants
Barnes, G. D., Eagle, K. A., & Froehlich, J. B. (2014) · Hospital Practice · doi:10.3810/hp.2014.08.1118 · Cited by 4
Anderson, M. R., Wilson, S. H., & Rosenblatt, M. A. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781316145227.019 · Cited by 4
Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding
Thalji, N. K., & Camire, R. M. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000369 · Cited by 4
Neue orale Antikoagulanzien aus unfallchirurgischer Sicht
Siebenlist, S., Haas, S. K., Elser, F., & Stöckle, U. (2010) · Der Unfallchirurg · doi:10.1007/s00113-010-1878-5 · Cited by 5
Self-citationA cost-analysis model for anticoagulant treatment in the hospital setting
Mody, S. H., Huynh, L. Y., Zhuo, Y. D., Tran, K. N., Lefèbvre, P., & Bookhart, B. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.914032 · Cited by 5
Oliveira, L. A. S., Mendes, L. H., Filho, N. N. C., & Valladão, V. D. C. S. (2026) · Cureus · doi:10.7759/cureus.110817 · Cited by 3
“However, evidence specific to plastic surgery remains limited, with most available data extrapolated from orthopedic surgery [28].”
Ng, H. J., Chee, Y. L., Kuperan, P., Lim, L. C., Tan, D. C. L., Tay, J. C., Handa, P. K., Ali, M. A., & Lee, L. H. (2013) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v42n11p593 · Cited by 3
New anticoagulants: pharmacology and clinical studies
Samama, C. M. (2011) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-011-0875-9 · Cited by 3
“The first results for long-term prophylaxis (35 days) with rivaroxaban after hip surgery are promising (RECORD 1 study) [4].”
BackgroundBiggi, F., Randelli, F., Rocca, C. D., Imberti, D., Grossi, P., Landolfi, R., Palareti, G., & Prisco, D. (2010) · LO SCALPELLO-OTODI Educational · doi:10.1007/s11639-010-0085-z · Cited by 3
The Efficacy of Rivaroxaban in Patients With Atrial Fibrillation
Carag, M. R., & Arora, R. R. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3182491d8b · Cited by 4
The Role of Novel Anticoagulants in the Management of Venous Thromboembolic Disease
Bott‐Kitslaar, D. M., Wysokiński, W. E., & McBane, R. D. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0326-1 · Cited by 3
los nuevos anticoagulantes orales: una realidad
Ruiz, L. F. G.-F., & Solís-Ayala, E. (2013) · Medicina Interna de México · Cited by 3
Wood, A. M., Smith, R., Keenan, A., Brenkel, I. J., & Walmsley, P. (2014) · Journal of Arthroscopy and Joint Surgery · doi:10.1016/j.jajs.2014.07.001 · Cited by 3
Evaluation of an oral direct factor Xa inhibitor anticoagulant in healthy adult horses
Rodríguez‐Pozo, M. L., Armengou, L., Monreal, L., Viu, J., Cesarini, C., & José‐Cunilleras, E. L. V. (2016) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.12540 · Cited by 3
Kerkar, P. G., Bose, D., Nishandar, T., Sabnis, G., Kumar, D., Thatte, U. M., & Gogtay, N. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.06.006 · Cited by 3
Isaac, H., Arnold, K. E., Pagedar, N. A., Buchakjian, M. R., & Arnold, K. E. (2024) · Otolaryngology · doi:10.1002/ohn.875 · Cited by 3
NOACs for VTE prevention in patients with lower limb fracture: a systematic review and meta-analysis
Wu, B., Sun, L., Wu, W., Cao, J., Chen, Y., & Yan, C. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-06092-5 · Cited by 3
“Clinical trials [33, 34] have demonstrated that rivaroxaban significantly outperforms enoxaparin in preventing VTE and achieves superior efficacy in reducing symptomatic VTE events while maintaining an equivalent safety profile with regard to bleeding complications.”
He, S., Yin, X., Xu, Y., & Zhong, Z. (2025) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2025.10.1318 · Cited by 3
Clinical Development of Rivaroxaban: Emerging New Clinical evidences?
Mont, L., Marín, F. R., Garcia-Bragado, F., Martínez, M. S., & Culleré, J. G. (2015) · Future Cardiology · doi:10.2217/fca.15.31 · Cited by 3
Shantsila, E., & Lip, G. Y. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-25460-9_2 · Cited by 3
Vascular Engineering of Blood Coagulation
Goto, S. (2016) · Springer eBooks · doi:10.1007/978-4-431-54801-0_11 · Cited by 3
Fatal pulmonary thromboembolism after Achilles tendon open repair: A rare case report
Chun, D., Lee, J.-H., Won, S. H., & Cho, J. (2017) · Medicine · doi:10.1097/md.0000000000008887 · Cited by 3
Rainville, T., Laskine, M., & Durand, M. (2019) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2018-111057 · Cited by 3
Rodarte, R. R. P., Guimaräes, J. A. M., Franco, J. S., Fonseca, L., Nascimento, V., Aramburu, J. P. G., & Barretto, J. M. (2019) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-6991e-20192075 · Cited by 3
Abutorabi, A., Ahmadi, M. H., Faradonbeh, S. B., Kemmak, A. R., & Alipour, V. (2023) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.37.20 · Cited by 6
“0959 Lassen et al (25),errikson et al (26) DVT 0.”
BackgroundRen, J., Wang, N., Zhang, X., Song, F., Zheng, X. M., & Han, X. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05767-z · Cited by 3
“Finally, 18 RCTs with a total of 59,724 patients met the inclusion criteria: RECORD1-4 [28–31], EINSTEIN-DVT [32], EINSTEIN-PE [33], ROCKET AF [34 ], MAGELLAN [ 35], ATLAS ACS 2-TIMI 51 [36], EINSTEIN-CHOICE [37], Einstein-Extension [32], ATLAS ACS-TIMI 46 [38], CASSINI [39 ], AFIRE UMIN AF-PCI…”
Schenk, J. F., Stephan, B., Kusma, M., Groß, J., & Eichler, H. (2009) · Der Orthopäde · doi:10.1007/s00132-009-1455-1 · Cited by 4
Orally Administered Factor Xa Inhibitor, Rivaroxaban: A Novel Thromboembolic Prophylaxis Agent
Komotar, R. J., Starke, R. M., & Connolly, E. S. (2008) · Neurosurgery · doi:10.1227/01.neu.0000339454.55968.f0 · Cited by 3
Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update
Goff, T. A. J., Kontakis, G. M., & Giannoudis, P. V. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.558500 · Cited by 3
“The RECORD (Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism) study program involved > 12,500 patients across four randomized, placebo-controlled, double-blind and double-dummy studies [34-37].”
BackgroundInnasimuthu, A. L., Kumar, S., Akter, S., & BORER, J. S. (2013) · Cardiology · doi:10.1159/000353484 · Cited by 3
Brosa, M., Monréal, M., & Piñol, C. (2012) · PharmacoEconomics Spanish Research Articles · doi:10.1007/bf03320872 · Cited by 4
Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients
Kwong, L. M., & Turpie, A. G. G. (2015) · Current Orthopaedic Practice · doi:10.1097/bco.0000000000000232 · Cited by 3
[Prophylaxis of venous thromboembolic disease in high-risk orthopedic surgery].
Reyes, G. E. M., Gómez, R. E., Sánchez, A. M. D. C., Espinosa-Larrañaga, F., Guzmán, M. Á. E. M., González, R. T., la Fuente-Zuno, J. C. D., Huerta, J. V. M., Garduño, E. V., Cymet-Ramírez, J., et al. (2012) · PubMed · Cited by 3
Prevention and treatment of venous thromboembolism in older people
Veiraiah, A., Shetty, H. G. M., & Routledge, P. (2008) · Reviews in Clinical Gerontology · doi:10.1017/s0959259809002871 · Cited by 3
Pebanco, G. D. O., Kaiser, S., & Haines, S. T. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r247 · Cited by 5
New aspects on treatment modalities for thromboembolic episodes
Schulman, S. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02242.x · Cited by 4
Oral Factor Xa and Direct Thrombin Inhibitors: A Clinical Perspective
Thethi, I., Lewis, B., & Fareed, J. (2012) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e318248bc4c · Cited by 4
Outpatient Oral Anticoagulant Therapy
Ansell, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00037-6 · Cited by 4
Pulmonary Embolism and Deep Vein Thrombosis
Goldhaber, S. Z., & Piazza, G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00038-2 · Cited by 5
Anticoagulant, Antiplatelet, and Thrombolytic Drugs
Green, L., & Machin, S. J. (2012) · Wiley eBooks · doi:10.1002/9781444398595.ch41 · Cited by 6
Imberti, D., & Prisco, D. (2007) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000252816 · Cited by 4
“Four phase III trials have been conducted to evaluate the efficacy and the safety of rivaroxaban in the prophylaxis of VTE in major orthopedic surgery of the lower extremities. They have been called RECORD studies, which is the acronym for Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombos…”
MethodSimplifying Thromboprophylaxis Could Improve Outcomes in Orthopaedic Surgery
Friedman, R. J. (2010) · Thrombosis · doi:10.1155/2010/108049 · Cited by 4
“Rivaroxaban has shown potential as a once-daily, oral anticoagulant that may be administered in fixed doses for the prevention and treatment of thromboembolic disorders following orthopaedic surgery [47–52].”
BackgroundSelf-citationNew Oral Anticoagulants for Thromboprophylaxis after Elective Total Hip and Knee Arthroplasty
Friedman, R. J. (2010) · Thrombosis · doi:10.1155/2010/280731 · Cited by 14
“…the unmet clinical needs with current agents, discuss the new classes of oral agents, present data on the new oral agents currently available in the European Union (EU) and other countries, and discuss how these agents might meet the needs of orthopaedic surgeons and internists in VTE prophylaxis.”
BackgroundSelf-citationLussana, F., Cattaneo, M., & Squizzato, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-01-0073 · Cited by 4
“The experimental drug was dabigatran in two studies (23, 24), apixaban in one (28), and rivaroxaban in two (18, 19).”
BackgroundXuan, D., McBride, S. J., Wastall, P., Porcari, A. R., DiCarlo, L. A., & Boyd, R. A. (2015) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.232 · Cited by 3
Anticoagulation and Non-urgent Commercial Air Travel: A Review of the Literature
Nunnally, B., Josseaume, J., Duchateau, F. X., O’Connor, R. E., Verner, L., & Brady, W. J. (2015) · Air Medical Journal · doi:10.1016/j.amj.2015.06.006 · Cited by 3
Primary prevention of venous thromboembolism
Figueiredo, R., Stansby, G. P., & Bhattacharya, V. (2012) · Phlebology The Journal of Venous Disease · doi:10.1258/phleb.2012.012s32 · Cited by 4
Kardiovaskuläre Pharmakotherapie: Risiken und Nebenwirkungen
Voigt, N., Heijman, J., & Dobrev, D. (2014) · Herz · doi:10.1007/s00059-014-4066-5 · Cited by 4
Perioperative care of the rheumatic disease patient
MacKenzie, C. R., & Paget, S. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00067-1 · Cited by 3
Recomendações da SBA para segurança na anestesia regional em uso de anticoagulantes
Fonseca, N. M., de Anestesiologia, S. B., Alves, R. R., & Pontes, J. P. J. (2013) · Brazilian Journal of Anesthesiology · doi:10.1016/j.bjan.2013.04.008 · Cited by 5
Metadata
- Authors
- Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., & Geerts, W.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Aarhus University Hospital (DK)
- Medical University of South Carolina (US)
- Technical University of Munich (DE)
- Leiden University Medical Center (NL)
- Queen Mary University of London (GB)
- Bayer (Germany) (DE)
- University of Toronto (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-06-26
- Volume
- 358
- Issue
- 26
- Pages
- 2765-2775
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2014491911
- Cited by
- 1,433
- References
- 25
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 24 · 2023: 35 · 2022: 39 · 2021: 55 · 2020: 47 · 2019: 47 · 2018: 60 · 2017: 68 · 2016: 86 · 2015: 92 · 2014: 98 · 2013: 167 · 2012: 159
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, venous thromboembolism, deep vein thrombosis, pulmonary embolism, factor Xa inhibitors, major bleeding, postoperative anticoagulation
- MeSH terms
- Rivaroxaban, Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thrombosis, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.